DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CEFPROZIL
Clinical Trials for Cefprozil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00778245 | Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2005-05-01 | The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions. |
| NCT00778557 | Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2005-06-01 | The study was conducted as a blinded, randomized, 3-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fasting conditions |
| NCT00778739 | Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2005-06-01 | The study was conducted as an open-label, randomized, 2-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fed conditions |
| NCT00778778 | Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2005-05-01 | The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fasting conditions. |
| NCT00835354 | Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-05-01 | The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions. |
| NCT00835614 | Cefprozil for Oral Suspension 250 mg/5 mL, Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-04-01 | The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions. |
| NCT00840281 | Cefprozil 500 mg Tablets Under Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2003-09-01 | The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets (Teva Pharmaceuticals USA) with that of Cefzil® 500 mg tablets (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cefprozil
Condition Name
Clinical Trial Locations for Cefprozil
Trials by Country
Clinical Trial Progress for Cefprozil
Clinical Trial Phase
Clinical Trial Sponsors for Cefprozil
Sponsor Name
